Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE® (alpelisib) tablets, for oral use VIJOICE® (alpelisib) oral granules Initial U.S. Approval: 2019
Medication labelWhy this: Advisory · dailymed-prescription
VIJOICE is indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
- generic_name
- alpelisib
- product_names
- alpelisib
- ndc
- 0078-1021, 0078-1021-51, 0078-1021-84, 0078-1021-90, 0078-1021-91, 0078-1028, 0078-1028-51, 0078-1028-84, 0078-1028-90, 0078-1028-91, 0078-1035, 0078-1035-61, 0078-1035-02, 0078-1035-94, 0078-1035-92, 0078-1133, 0078-1140, 0078-1175, 0078-1175-19, 0078-1175-51
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en